Effect of palivizumab on wheezing after respiratory syncytial virus (RSV) infectio

Not Applicable

Completed

• Conditions: Respiratory syncytial virus bronchiolitis and post-bronchiolitis wheezing; Respiratory; Acute bronchitis

• Registration Number: ISRCTN73641710
• Lead Sponsor: niversity Medical Centre Utrecht (UMCU) (Netherlands)

Brief Summary

2013 results in: http://www.ncbi.nlm.nih.gov/pubmed/23656644 2018 results in: http://www.ncbi.nlm.nih.gov/pubmed/29500030 2020 results in https://pubmed.ncbi.nlm.nih.gov/32203712/ (added 24/03/2020)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-01-23
• Study Completion: 2017-04-01
• Last Update Posted: 14 April 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 429

Inclusion Criteria

1. Healthy preterm infants
2. Gestational age between 32 and 35 weeks, either sex
3. Children of parents who master the Dutch language

Exclusion Criteria

1. A known cardiac anomaly, Down's syndrome or other serious congenital disorders
2. Require intensive respiratory treatment, defined as surfactant treatment or at least 2 weeks of mechanical ventilation
3. Greater than 6 months of age at the start of the RSV season, defined as 1st October of the year of birth
4. Airway morbidity before the start of the RSV season, monitored before the first injection

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of wheezing days during the first year of life